Archives of 2017

We presented three posters at ICPE Montreal

30.08.2017 – We presented three posters at ICPE Montreal, the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. The conference was held in Montreal August 26 – August 30, 2017. We presented the following posters: Spotlight poster: Adjusting for unobserved disease severity using individuals as their own controls – An example from a schizophrenia study Pioglitazone […]

Attendance at ICPE 2017 in Montreal, Canada

26.6.2017 – We are proud to sponsor 33rd ICPE, International Conference on Pharmacoepidemiology & Therapeutic Risk Management, that will be held in Montreal, Canada this year. We look forward to meeting you! We will have an exhibition booth there for you to find us easily and to give you more information about the pharmacoepidemiological Real-World […]

New article on pharmacological treatments and risk of readmission to hospital for unipolar depression

01.06.2017 – Our new article on pharmacological treatments and risk of readmission to hospital for unipolar depression has been published in The Lancet. Little is known about the comparative effectiveness of long-term pharmacological treatments for severe unipolar depression. We aimed to study the effectiveness of pharmacological treatments in relapse prevention in a nationwide cohort of […]

New article on pioglitazone use and risk of mortality in patients with type 2 diabetes

30.5.2017 – Our new article on pioglitazone use and risk of mortality in patients with type 2 diabetes has been published in BMJ Open. Life expectancy is 5–10 years shorter in adult patients with newly-diagnosed diabetes than in the general population. Cardiovascular diseases are the leading cause of death in this patient group. Pioglitazone, which is an oral […]

New article on oral anticoagulation therapy among patients with atrial fibrillation

27.4.2017 – Our new article on oral anticoagulation therapy among patients with atrial fibrillation has been published in Pharmacoepidemiology and Drug Safety. Use of oral anticoagulation therapy remarkable decreases the risk of stroke and other thromboembolic events in patients with atrial fibrillation (AF). Despite of newer anticoagulants on the market, warfarin still is the most commonly used […]

StatFinn and EPID Research present strong growth in 2016

11.04.2017 – StatFinn and EPID Research achieved strong and profitable growth in 2016. Following the 2-digit growth from the previous financial year, the results show that the merged company continues the global expansion with solid basis, resources and talent. Read more details in the official press release. Press release EN – Press release FI

New article on antipsychotic treatments effectiveness among patients with schizophrenia

02.04.2017 – Our new article on Real-world effectiveness of antipsychotic treatments among patients with schizophrenia and affective symptoms has been published on European Psychiatry. In an evaluation of 22 specific antipsychotic treatments against the most frequently used antipsychotic quetiapine, it was found that the lowest rehospitalization risks were observed during the treatment periods of olanzapine long-acting injection, […]
  • 1
  • 2